Agenus to Host First 2026 Stakeholder Webcast

Core Viewpoint - Agenus Inc. is set to host its first Stakeholder Webcast of 2026, focusing on the global momentum of its botensilimab and balstilimab (BOT+BAL) program as it enters the new year [1][2]. Group 1: Webcast Details - The webcast will take place on January 28, 2026, at 4:00 p.m. ET and will feature insights from Agenus leadership and an international oncology expert [1][2]. - The session will include a live Q&A, allowing stakeholders to submit questions in advance [3]. Group 2: Featured Topics and Speakers - Garo Armen, PhD, will discuss a recent strategic collaboration with Zydus Lifesciences, emphasizing its role in strengthening Agenus' global development and patient access programs for BOT+BAL [4]. - Professor Robin Jones will provide a clinical perspective on the expansion of France's Autorisation d'Accès Compassionnel (AAC) program to include sarcoma patients, highlighting the unmet medical needs in this area [5]. - José Iglesias, MD, will address the expansion of Agenus' global medical affairs organization and its support for authorized access pathways as the BOT+BAL program progresses through Phase 3 evaluation [6]. Group 3: Company Overview - Agenus is a leading immuno-oncology company with a comprehensive pipeline of immunological agents, founded in 1994 [8]. - The company aims to expand patient populations benefiting from cancer immunotherapy through various therapeutic approaches, including antibody therapeutics and adoptive cell therapies [8]. Group 4: Product Information - Botensilimab is designed to enhance anti-tumor immune responses and has shown clinical responses across nine metastatic, late-line cancers, with approximately 1,200 patients treated in clinical trials [10][11]. - Balstilimab is a fully human monoclonal antibody that blocks PD-1 and has been evaluated in over 900 patients, demonstrating clinical activity across several tumor types [12].